In this episode, which is the last episode of the year (the team will be back in January!), Ayesha discusses the FDA approval of Biohaven’s intranasal spray Zavegepant for the acute treatment of migraines. The drug is the first CGRP receptor antagonist in a nasal spray formulation. Some of the editorial team members shared their experiences with migraine headaches, and talked about the pros and cons of an intranasal spray for helping treat them.
The team also talked about results from an early-stage trial evaluating Moderna’s new mRNA-based influenza vaccine in adults. The results showed that the vaccine had no serious safety concerns and elicits immune responses against four different strains of the influenza virus. An mRNA-based flu shot can be developed more rapidly than a traditional flu shot. This means it can be designed closer to flu season when there is a better picture of which influenza virus strains may predominate that season, allowing for greater accuracy and hence greater effectiveness. Moderna is also developing a combo vaccine against COVID-19, influenza and RSV.
Read the full articles here:
Biohaven Eyes FDA Approval for Second Migraine Drug Zavegepant After Promising Trial Results
Moderna Reveals Positive Results for its mRNA Influenza Vaccine
The weekly podcast is available for streaming every Wednesday on Spotify, Apple Music and wherever you stream your podcasts.
Subscribe to the Xtalks Life Science Podcast to never miss a new episode.
Join or login to leave a comment
JOIN LOGIN